| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 92 | 2024 | 13446 | 6.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 64 | 2024 | 5379 | 6.000 |
Why?
|
| Pneumonia | 21 | 2023 | 2158 | 4.680 |
Why?
|
| Lung Diseases, Interstitial | 30 | 2024 | 940 | 3.420 |
Why?
|
| Tomography, X-Ray Computed | 83 | 2024 | 20690 | 2.430 |
Why?
|
| Tumor Burden | 15 | 2023 | 1888 | 2.240 |
Why?
|
| Diagnostic Imaging | 14 | 2024 | 3530 | 2.010 |
Why?
|
| Protein Kinase Inhibitors | 22 | 2022 | 5691 | 1.960 |
Why?
|
| Solitary Pulmonary Nodule | 5 | 2023 | 280 | 1.860 |
Why?
|
| Antineoplastic Agents | 21 | 2023 | 13631 | 1.690 |
Why?
|
| Lung | 47 | 2024 | 10046 | 1.580 |
Why?
|
| Radiology | 11 | 2024 | 2105 | 1.510 |
Why?
|
| Awards and Prizes | 3 | 2020 | 364 | 1.450 |
Why?
|
| Lung Diseases | 12 | 2023 | 1939 | 1.390 |
Why?
|
| Thymus Hyperplasia | 3 | 2015 | 32 | 1.380 |
Why?
|
| Exhalation | 9 | 2019 | 185 | 1.360 |
Why?
|
| Immunotherapy | 18 | 2021 | 4746 | 1.240 |
Why?
|
| Thymus Neoplasms | 4 | 2018 | 270 | 1.220 |
Why?
|
| Thoracic Neoplasms | 3 | 2021 | 267 | 1.180 |
Why?
|
| Quinazolines | 5 | 2016 | 1366 | 1.180 |
Why?
|
| Antibodies, Monoclonal | 12 | 2018 | 9239 | 1.160 |
Why?
|
| Neoplasms | 24 | 2023 | 22340 | 1.080 |
Why?
|
| Thorax | 4 | 2023 | 554 | 1.040 |
Why?
|
| Radiography, Thoracic | 12 | 2020 | 1319 | 1.020 |
Why?
|
| Pseudolymphoma | 2 | 2015 | 30 | 0.930 |
Why?
|
| Radiographic Image Enhancement | 7 | 2014 | 873 | 0.910 |
Why?
|
| Sarcoidosis, Pulmonary | 2 | 2018 | 45 | 0.900 |
Why?
|
| Humans | 228 | 2024 | 765926 | 0.820 |
Why?
|
| Melanoma | 10 | 2019 | 5695 | 0.810 |
Why?
|
| Alveolitis, Extrinsic Allergic | 2 | 2021 | 62 | 0.790 |
Why?
|
| Thoracic Diseases | 2 | 2017 | 99 | 0.770 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 7 | 2023 | 519 | 0.760 |
Why?
|
| Granuloma | 3 | 2018 | 329 | 0.760 |
Why?
|
| Neuroendocrine Tumors | 3 | 2018 | 655 | 0.760 |
Why?
|
| Aged, 80 and over | 66 | 2023 | 59496 | 0.740 |
Why?
|
| Aged | 108 | 2024 | 171163 | 0.740 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2020 | 173 | 0.740 |
Why?
|
| Molecular Targeted Therapy | 10 | 2021 | 2823 | 0.700 |
Why?
|
| Radiography | 9 | 2024 | 6941 | 0.690 |
Why?
|
| Radiation Pneumonitis | 2 | 2020 | 98 | 0.690 |
Why?
|
| Middle Aged | 111 | 2024 | 223016 | 0.670 |
Why?
|
| Mutation | 32 | 2023 | 30192 | 0.660 |
Why?
|
| Immunoconjugates | 3 | 2023 | 976 | 0.650 |
Why?
|
| Pulmonary Embolism | 8 | 2023 | 2596 | 0.640 |
Why?
|
| Disease Progression | 18 | 2024 | 13614 | 0.610 |
Why?
|
| Male | 121 | 2024 | 363815 | 0.590 |
Why?
|
| Thymus Gland | 3 | 2015 | 1259 | 0.580 |
Why?
|
| Female | 130 | 2024 | 396141 | 0.570 |
Why?
|
| Diaphragm | 5 | 2019 | 356 | 0.570 |
Why?
|
| Bronchiectasis | 3 | 2022 | 141 | 0.570 |
Why?
|
| Lymphoma | 2 | 2016 | 1896 | 0.560 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2015 | 8924 | 0.540 |
Why?
|
| Periodicals as Topic | 4 | 2020 | 1463 | 0.530 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 6360 | 0.520 |
Why?
|
| Tomography, Spiral Computed | 4 | 2005 | 273 | 0.510 |
Why?
|
| Adult | 85 | 2023 | 223088 | 0.500 |
Why?
|
| Pulmonary Emphysema | 6 | 2021 | 683 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7423 | 0.490 |
Why?
|
| Ovarian Diseases | 3 | 2006 | 133 | 0.470 |
Why?
|
| Gene Rearrangement | 2 | 2016 | 1143 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2020 | 561 | 0.460 |
Why?
|
| Retrospective Studies | 50 | 2024 | 81537 | 0.460 |
Why?
|
| Mediastinal Cyst | 1 | 2014 | 30 | 0.450 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2018 | 3183 | 0.450 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2024 | 1225 | 0.450 |
Why?
|
| Lung Transplantation | 1 | 2023 | 1311 | 0.430 |
Why?
|
| Internship and Residency | 5 | 2019 | 5945 | 0.430 |
Why?
|
| Respiratory Function Tests | 10 | 2019 | 1692 | 0.410 |
Why?
|
| Exons | 5 | 2020 | 2393 | 0.400 |
Why?
|
| Mucin-5B | 6 | 2023 | 148 | 0.400 |
Why?
|
| Neoplasm Staging | 12 | 2021 | 11196 | 0.390 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 488 | 0.390 |
Why?
|
| Treatment Outcome | 32 | 2023 | 65194 | 0.390 |
Why?
|
| Arthritis, Rheumatoid | 7 | 2024 | 3743 | 0.380 |
Why?
|
| Genomics | 11 | 2024 | 5925 | 0.380 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2023 | 1763 | 0.380 |
Why?
|
| Emphysema | 2 | 2021 | 234 | 0.380 |
Why?
|
| Positron-Emission Tomography | 5 | 2015 | 6542 | 0.380 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 583 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 2046 | 0.370 |
Why?
|
| Pregnancy, Ectopic | 2 | 2003 | 146 | 0.370 |
Why?
|
| Japan | 4 | 2019 | 1411 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 5333 | 0.360 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 10 | 2024 | 3247 | 0.360 |
Why?
|
| Pyridines | 3 | 2017 | 2885 | 0.350 |
Why?
|
| NF-E2-Related Factor 2 | 5 | 2024 | 385 | 0.340 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 6838 | 0.340 |
Why?
|
| Pyrazoles | 3 | 2017 | 2031 | 0.340 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 2885 | 0.340 |
Why?
|
| Survival Rate | 10 | 2023 | 12822 | 0.330 |
Why?
|
| Hemosiderosis | 1 | 2010 | 66 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11858 | 0.330 |
Why?
|
| Respiration | 5 | 2019 | 1653 | 0.330 |
Why?
|
| Leiomyoma | 2 | 2005 | 644 | 0.320 |
Why?
|
| Peristalsis | 2 | 2006 | 60 | 0.310 |
Why?
|
| Medical Oncology | 3 | 2021 | 2339 | 0.310 |
Why?
|
| Sirolimus | 1 | 2015 | 1541 | 0.300 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2006 | 170 | 0.300 |
Why?
|
| Uterine Contraction | 2 | 2006 | 90 | 0.290 |
Why?
|
| Bronchial Diseases | 2 | 2006 | 151 | 0.290 |
Why?
|
| Inhalation | 2 | 2005 | 142 | 0.290 |
Why?
|
| Pulmonary Fibrosis | 4 | 2021 | 503 | 0.280 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 2419 | 0.280 |
Why?
|
| Observer Variation | 5 | 2020 | 2611 | 0.270 |
Why?
|
| Smoking | 9 | 2024 | 9082 | 0.270 |
Why?
|
| Pleura | 2 | 2019 | 241 | 0.270 |
Why?
|
| Iohexol | 3 | 2014 | 205 | 0.270 |
Why?
|
| Gene Amplification | 2 | 2023 | 1088 | 0.270 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 445 | 0.270 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 2844 | 0.260 |
Why?
|
| Incidence | 10 | 2023 | 21513 | 0.260 |
Why?
|
| Sarcoidosis | 2 | 2017 | 533 | 0.260 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 1075 | 0.260 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2015 | 1076 | 0.260 |
Why?
|
| Cohort Studies | 21 | 2022 | 41680 | 0.260 |
Why?
|
| Computers, Handheld | 2 | 2004 | 211 | 0.250 |
Why?
|
| Nuclear Proteins | 6 | 2023 | 5782 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 9373 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6503 | 0.250 |
Why?
|
| Prognosis | 14 | 2020 | 29890 | 0.240 |
Why?
|
| Uterine Neoplasms | 2 | 2005 | 1425 | 0.240 |
Why?
|
| Kidney Neoplasms | 5 | 2018 | 4278 | 0.240 |
Why?
|
| Hemorrhage | 4 | 2017 | 3466 | 0.240 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 20133 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2018 | 36547 | 0.230 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 4349 | 0.230 |
Why?
|
| Artifacts | 5 | 2006 | 1896 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 4044 | 0.230 |
Why?
|
| Forced Expiratory Volume | 4 | 2019 | 1828 | 0.220 |
Why?
|
| Molecular Imaging | 1 | 2011 | 822 | 0.220 |
Why?
|
| Image Enhancement | 2 | 2013 | 2857 | 0.220 |
Why?
|
| Contrast Media | 8 | 2014 | 5330 | 0.220 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2006 | 1093 | 0.220 |
Why?
|
| Hemangioendothelioma | 1 | 2004 | 112 | 0.210 |
Why?
|
| DNA Helicases | 3 | 2023 | 852 | 0.210 |
Why?
|
| Adnexal Diseases | 1 | 2004 | 104 | 0.210 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 9065 | 0.210 |
Why?
|
| Camptothecin | 2 | 2023 | 598 | 0.210 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2003 | 95 | 0.210 |
Why?
|
| Bronchi | 2 | 2006 | 843 | 0.210 |
Why?
|
| Computer Communication Networks | 1 | 2004 | 292 | 0.200 |
Why?
|
| Diagnosis, Differential | 8 | 2014 | 12973 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3109 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3231 | 0.200 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 167 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2018 | 637 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 3716 | 0.200 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 3111 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2016 | 3458 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2015 | 1535 | 0.180 |
Why?
|
| Republic of Korea | 1 | 2023 | 583 | 0.180 |
Why?
|
| Prevalence | 8 | 2024 | 15828 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2018 | 960 | 0.180 |
Why?
|
| Respiratory System Abnormalities | 1 | 2021 | 67 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3661 | 0.170 |
Why?
|
| Pandemics | 1 | 2020 | 8721 | 0.170 |
Why?
|
| Fatty Liver | 2 | 2005 | 810 | 0.170 |
Why?
|
| Infectious Disease Medicine | 1 | 2020 | 50 | 0.170 |
Why?
|
| Phospholipase D | 1 | 2019 | 71 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2015 | 3498 | 0.160 |
Why?
|
| Iceland | 4 | 2020 | 183 | 0.160 |
Why?
|
| Genes, cdc | 1 | 2019 | 113 | 0.160 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2003 | 335 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 1621 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1881 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 833 | 0.160 |
Why?
|
| Portugal | 1 | 2018 | 91 | 0.150 |
Why?
|
| Histiocytosis | 1 | 2018 | 40 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2024 | 3360 | 0.150 |
Why?
|
| Posture | 3 | 2017 | 955 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 160 | 0.150 |
Why?
|
| Tamoxifen | 1 | 2003 | 964 | 0.150 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2015 | 60 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 2053 | 0.150 |
Why?
|
| Tidal Volume | 2 | 2019 | 519 | 0.150 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 223 | 0.150 |
Why?
|
| Total Lung Capacity | 3 | 2015 | 148 | 0.150 |
Why?
|
| Thailand | 1 | 2018 | 288 | 0.150 |
Why?
|
| Risk Factors | 12 | 2023 | 74850 | 0.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 261 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 5836 | 0.140 |
Why?
|
| Follow-Up Studies | 11 | 2024 | 39228 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10426 | 0.140 |
Why?
|
| Benzeneacetamides | 1 | 2017 | 36 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2021 | 301 | 0.140 |
Why?
|
| Professional Competence | 1 | 2020 | 429 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2021 | 10086 | 0.140 |
Why?
|
| North America | 1 | 2020 | 1287 | 0.140 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8522 | 0.140 |
Why?
|
| Polymorphism, Genetic | 3 | 2017 | 4249 | 0.140 |
Why?
|
| Retreatment | 1 | 2018 | 598 | 0.130 |
Why?
|
| Oximes | 1 | 2018 | 305 | 0.130 |
Why?
|
| Movement | 3 | 2019 | 1460 | 0.130 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 1378 | 0.130 |
Why?
|
| Mammography | 2 | 2005 | 2424 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 2877 | 0.130 |
Why?
|
| Pleural Diseases | 1 | 2017 | 138 | 0.130 |
Why?
|
| Young Adult | 13 | 2023 | 59857 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2510 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 384 | 0.120 |
Why?
|
| Asbestos | 1 | 2017 | 250 | 0.120 |
Why?
|
| Receptor, trkA | 1 | 2016 | 159 | 0.120 |
Why?
|
| Causality | 1 | 2021 | 1247 | 0.120 |
Why?
|
| Hormone Antagonists | 1 | 2015 | 108 | 0.120 |
Why?
|
| Internationality | 1 | 2020 | 1007 | 0.120 |
Why?
|
| Thyroiditis | 1 | 2015 | 85 | 0.120 |
Why?
|
| Prednisolone | 1 | 2016 | 323 | 0.120 |
Why?
|
| Prednisone | 1 | 2019 | 1566 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2016 | 238 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 931 | 0.110 |
Why?
|
| Lung Volume Measurements | 2 | 2006 | 381 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2010 | 4037 | 0.110 |
Why?
|
| Spirometry | 4 | 2021 | 929 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 452 | 0.110 |
Why?
|
| Remission Induction | 2 | 2019 | 2413 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 715 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2021 | 2601 | 0.110 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 4882 | 0.110 |
Why?
|
| Forecasting | 1 | 2023 | 2936 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2015 | 316 | 0.110 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 310 | 0.110 |
Why?
|
| Hepatitis | 1 | 2015 | 226 | 0.110 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 314 | 0.110 |
Why?
|
| Vital Capacity | 3 | 2024 | 995 | 0.110 |
Why?
|
| Receptor, erbB-2 | 1 | 2023 | 2592 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 2015 | 4904 | 0.100 |
Why?
|
| Carcinoid Tumor | 1 | 2014 | 225 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 14643 | 0.100 |
Why?
|
| Pyridones | 1 | 2018 | 816 | 0.100 |
Why?
|
| Thymoma | 1 | 2014 | 185 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2019 | 2027 | 0.100 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 4111 | 0.100 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 12529 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2019 | 1491 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 5784 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 1164 | 0.100 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 102 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 2559 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 15878 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 2945 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3238 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2023 | 12129 | 0.090 |
Why?
|
| Hormones | 1 | 2015 | 865 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 710 | 0.090 |
Why?
|
| Venous Thromboembolism | 2 | 2016 | 1883 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2003 | 3314 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2010 | 58 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 1204 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2015 | 1964 | 0.090 |
Why?
|
| Cysts | 1 | 2015 | 684 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1590 | 0.090 |
Why?
|
| Consensus | 1 | 2020 | 3202 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 662 | 0.090 |
Why?
|
| Pectoralis Muscles | 1 | 2010 | 86 | 0.090 |
Why?
|
| Mutation, Missense | 2 | 2023 | 2589 | 0.080 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 329 | 0.080 |
Why?
|
| Terminology as Topic | 2 | 2015 | 1536 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2010 | 234 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2015 | 616 | 0.080 |
Why?
|
| Age Factors | 8 | 2021 | 18382 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 18292 | 0.080 |
Why?
|
| Prospective Studies | 12 | 2023 | 54807 | 0.080 |
Why?
|
| Vaccination | 1 | 2021 | 3430 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 619 | 0.080 |
Why?
|
| Headache | 1 | 2017 | 1261 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 8037 | 0.080 |
Why?
|
| Neutrophils | 1 | 2021 | 3769 | 0.080 |
Why?
|
| Taxoids | 1 | 2012 | 665 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2019 | 2701 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2015 | 1086 | 0.080 |
Why?
|
| Recurrence | 3 | 2020 | 8492 | 0.070 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5300 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 682 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2005 | 21069 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 12059 | 0.070 |
Why?
|
| Disease Management | 1 | 2018 | 2530 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1042 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11030 | 0.070 |
Why?
|
| Telomere | 2 | 2024 | 941 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 5450 | 0.070 |
Why?
|
| Colitis | 1 | 2015 | 1239 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 862 | 0.070 |
Why?
|
| Fetal Organ Maturity | 1 | 2006 | 83 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 841 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 12803 | 0.070 |
Why?
|
| Inflammasomes | 1 | 2012 | 545 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 2423 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2016 | 4520 | 0.070 |
Why?
|
| Ovarian Cysts | 1 | 2006 | 107 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 645 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2013 | 958 | 0.060 |
Why?
|
| Algorithms | 1 | 2006 | 14064 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1161 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 2726 | 0.060 |
Why?
|
| Serous Membrane | 1 | 2005 | 22 | 0.060 |
Why?
|
| Logistic Models | 5 | 2019 | 13273 | 0.060 |
Why?
|
| Cause of Death | 1 | 2016 | 3715 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2014 | 1304 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 1469 | 0.060 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 14745 | 0.060 |
Why?
|
| Mice | 8 | 2023 | 81782 | 0.060 |
Why?
|
| Aging | 2 | 2021 | 8725 | 0.060 |
Why?
|
| Tracheal Diseases | 1 | 2005 | 118 | 0.060 |
Why?
|
| Palliative Care | 1 | 2019 | 3640 | 0.060 |
Why?
|
| Myometrium | 1 | 2005 | 174 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10256 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6058 | 0.060 |
Why?
|
| Ligands | 2 | 2021 | 3272 | 0.060 |
Why?
|
| ROC Curve | 3 | 2017 | 3612 | 0.050 |
Why?
|
| Syndrome | 1 | 2010 | 3271 | 0.050 |
Why?
|
| Cartilage Diseases | 1 | 2005 | 159 | 0.050 |
Why?
|
| Thrombosis | 1 | 2017 | 2955 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2023 | 233 | 0.050 |
Why?
|
| Angiography | 2 | 2006 | 1589 | 0.050 |
Why?
|
| Torsion Abnormality | 1 | 2003 | 92 | 0.050 |
Why?
|
| Outpatients | 1 | 2011 | 1595 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15401 | 0.050 |
Why?
|
| Ascites | 1 | 2004 | 336 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2003 | 175 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 3430 | 0.050 |
Why?
|
| Endometrium | 1 | 2005 | 404 | 0.050 |
Why?
|
| Traction | 1 | 2022 | 112 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2017 | 4544 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2010 | 820 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 18074 | 0.050 |
Why?
|
| Rupture | 1 | 2003 | 444 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2023 | 228 | 0.050 |
Why?
|
| Computer-Assisted Instruction | 1 | 2005 | 368 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2005 | 658 | 0.050 |
Why?
|
| United States | 4 | 2020 | 72909 | 0.050 |
Why?
|
| Linear Models | 3 | 2019 | 5873 | 0.050 |
Why?
|
| Models, Biological | 2 | 2018 | 9443 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2002 | 179 | 0.050 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 822 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2022 | 330 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 719 | 0.050 |
Why?
|
| Sucrose | 1 | 2021 | 155 | 0.040 |
Why?
|
| Anticoagulants | 2 | 2016 | 4856 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2014 | 5987 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Chromosomes | 1 | 2023 | 578 | 0.040 |
Why?
|
| Pericardium | 1 | 2004 | 679 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2234 | 0.040 |
Why?
|
| Airway Obstruction | 1 | 2005 | 672 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 46 | 0.040 |
Why?
|
| Boston | 2 | 2024 | 9334 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2004 | 535 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2350 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 2002 | 457 | 0.040 |
Why?
|
| Animals | 8 | 2023 | 168735 | 0.040 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 198 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3604 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 576 | 0.040 |
Why?
|
| Probability | 1 | 2024 | 2474 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2024 | 1865 | 0.040 |
Why?
|
| Fetus | 1 | 2006 | 1878 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2012 | 4909 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 5088 | 0.040 |
Why?
|
| Endometriosis | 1 | 2006 | 869 | 0.040 |
Why?
|
| Biopsy | 1 | 2010 | 6766 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 6958 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3801 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2020 | 22228 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2015 | 6321 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2019 | 426 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7473 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2021 | 596 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3249 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2003 | 1069 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 1775 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2021 | 9656 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 17060 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15645 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 329 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 921 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 1086 | 0.030 |
Why?
|
| Genotype | 3 | 2017 | 13026 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2021 | 1186 | 0.030 |
Why?
|
| X-Rays | 1 | 2016 | 309 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 543 | 0.030 |
Why?
|
| Fever | 1 | 2003 | 1607 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2015 | 49 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 539 | 0.030 |
Why?
|
| Bronchography | 2 | 2005 | 69 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1623 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 1937 | 0.030 |
Why?
|
| Breast | 1 | 2003 | 1950 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 312 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2019 | 698 | 0.030 |
Why?
|
| Apoptosis | 2 | 2020 | 9505 | 0.030 |
Why?
|
| Immune System | 1 | 2019 | 799 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2016 | 344 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2015 | 642 | 0.030 |
Why?
|
| Vitamin K | 1 | 2016 | 312 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 2530 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 8603 | 0.030 |
Why?
|
| Motion | 1 | 2016 | 782 | 0.030 |
Why?
|
| Pregnancy | 3 | 2006 | 30230 | 0.030 |
Why?
|
| Methotrexate | 1 | 2019 | 1719 | 0.030 |
Why?
|
| Internet | 1 | 2005 | 3106 | 0.030 |
Why?
|
| Equipment Design | 1 | 2020 | 3490 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 586 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 3431 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 1937 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 890 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 560 | 0.020 |
Why?
|
| Codon | 1 | 2013 | 599 | 0.020 |
Why?
|
| Registries | 2 | 2019 | 8346 | 0.020 |
Why?
|
| Problem Solving | 1 | 2014 | 442 | 0.020 |
Why?
|
| Sex Factors | 2 | 2015 | 10611 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1637 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 227 | 0.020 |
Why?
|
| Chemokines | 1 | 2015 | 956 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3049 | 0.020 |
Why?
|
| Bleomycin | 1 | 2012 | 491 | 0.020 |
Why?
|
| DNA Repair | 1 | 2020 | 2048 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 740 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2019 | 2630 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1886 | 0.020 |
Why?
|
| DNA Damage | 1 | 2020 | 2462 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3940 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2019 | 2155 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2012 | 711 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2045 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 634 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2017 | 1832 | 0.020 |
Why?
|
| Life Style | 1 | 2020 | 3928 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2653 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2013 | 2743 | 0.020 |
Why?
|
| China | 1 | 2015 | 2383 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 595 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 4780 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 1751 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2015 | 13042 | 0.020 |
Why?
|
| Patient Selection | 1 | 2019 | 4248 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3953 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4851 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7559 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 1331 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 1054 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 918 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2015 | 2114 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5377 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 1611 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1163 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 886 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 2688 | 0.020 |
Why?
|
| Floxuridine | 1 | 2005 | 44 | 0.020 |
Why?
|
| Tegafur | 1 | 2005 | 38 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6491 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1613 | 0.020 |
Why?
|
| Iopamidol | 1 | 2005 | 188 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8279 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 1489 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2645 | 0.010 |
Why?
|
| Walking | 1 | 2012 | 1198 | 0.010 |
Why?
|
| Programming Languages | 1 | 2005 | 133 | 0.010 |
Why?
|
| Venules | 1 | 2004 | 161 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2018 | 23597 | 0.010 |
Why?
|
| Cytokines | 1 | 2019 | 7417 | 0.010 |
Why?
|
| Exercise Test | 1 | 2012 | 2185 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2019 | 3458 | 0.010 |
Why?
|
| Uracil | 1 | 2005 | 210 | 0.010 |
Why?
|
| Sarcoma | 1 | 2015 | 1799 | 0.010 |
Why?
|
| Massachusetts | 1 | 2017 | 8882 | 0.010 |
Why?
|
| Research Design | 1 | 2019 | 6204 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 2895 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 539 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3592 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 1383 | 0.010 |
Why?
|
| Uterus | 1 | 2006 | 660 | 0.010 |
Why?
|
| Endosonography | 1 | 2006 | 626 | 0.010 |
Why?
|
| Systems Integration | 1 | 2004 | 425 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 2325 | 0.010 |
Why?
|
| Adolescent | 3 | 2023 | 88811 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2004 | 665 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 13398 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 13463 | 0.010 |
Why?
|
| Radiology Department, Hospital | 1 | 2004 | 409 | 0.010 |
Why?
|
| Age Distribution | 1 | 2006 | 2864 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 17596 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 16039 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 1648 | 0.010 |
Why?
|
| Glioma | 1 | 2015 | 3491 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4909 | 0.010 |
Why?
|
| Time Factors | 1 | 2021 | 40097 | 0.010 |
Why?
|
| Trachea | 1 | 2005 | 1091 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2005 | 1404 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2006 | 1945 | 0.010 |
Why?
|
| Gestational Age | 1 | 2006 | 3616 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 3542 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6544 | 0.010 |
Why?
|
| Child | 1 | 2023 | 80568 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 10380 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26282 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 22327 | 0.010 |
Why?
|